CDT (CDT Equity) Tariff Resilience Score: 6/10 (As of Jun. 28, 2026)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.64
! 5 Warning Signs
View Full Analysis

What is CDT Equity Tariff Resilience Score?

CDT Equity CDT -10.81% 10 Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 1,376 Biotechnology companies, CDT Equity ranks better than 75.94% on this metric.

CDT Equity has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

CDT Equity has Pharmaceuticals can face tariffs on raw materials. Global supply chain exposure, but industry often benefits from exemptions. Mitigation through diverse supplier base.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CDT Equity might have Average Resilient.

CDT Equity  (NAS:CDT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CDT Equity Tariff Resilience Score Related Terms

CDT vs PULM, ADIL, MBIO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CDT Equity's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CDT Equity Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CDT Equity's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CDT Equity's Tariff Resilience Score falls into.


CDT
10GF Score
CDT Equity Inc CDT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
CDT Equity (CDT) has a Tariff Resilience Score of 6 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CDT Equity ranks #331 out of 1376 companies in the Biotechnology industry, placing it in the top 24.1%.
Is CDT Equity's Tariff Resilience Score too high?
CDT Equity's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. CDT Equity's value of 6 is 50% above this industry median. Based on the distribution chart, CDT Equity ranks #331 out of 1376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Tariff Resilience Score compare to PULM and ADIL?
According to the Biotechnology industry distribution chart, CDT Equity ranks #331 out of 1376 companies for Tariff Resilience Score. This places CDT Equity in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CDT Equity's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CDT Equity's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CDT Equity's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CDT Equity (CDT), the current Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price